[Form 4] OCULAR THERAPEUTIX, INC Insider Trading Activity

Rhea-AI Filing Summary

Todd Anderman, Chief Legal Officer of Ocular Therapeutix, Inc. (OCUL), reported a non-discretionary sale of 11,132 shares of common stock on 10/08/2025 under a durable automatic sale instruction tied to a sell-to-cover election for the vesting of restricted stock units. The weighted-average price reported was $12.34, with individual sale prices ranging from $12.00 to $12.5114. Following the transaction, the reporting person beneficially owned 87,568 shares.

The sale was executed to satisfy tax withholding obligations and was not a discretionary trade by the reporting person. The reporting person adopted the automatic plan on 10/07/2024 and offered to provide detailed per-price sale information to the company or SEC staff upon request.

Positive

• Sale tied to tax withholding under a durable automatic plan, indicating non-discretionary execution
• Reporting person retains 87,568 shares after the transaction, preserving continued insider exposure

Negative

• Material number of shares sold (11,132) could slightly increase free float in the short term
• Weighted-average sale price $12.34 may signal realized proceeds below some prior trading levels (range down to $12.00)

Insights

Corporate Governance Analyst

TL;DR: Officer sold shares via a pre-established sell-to-cover plan to satisfy RSU taxes; ownership remains material.

The transaction reflects a routine sell-to-cover tied to vested restricted stock units rather than a discretionary market sale. The reporting person sold 11,132 shares at a weighted-average price of $12.34 on 10/08/2025, and still beneficially owns 87,568 shares after the sale.

Key dependencies include the vesting schedule and the automatic sale instruction adopted on 10/07/2024. Stakeholders may note that the sale was explicitly non-discretionary; provide-per-price details are available on request and clarify execution timing if needed in the near term.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Anderman Todd

(Last) (First) (Middle)

C/O OCULAR THERAPEUTIX, INC.

15 CROSBY DRIVE

(Street)

BEDFORD MA 01730

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
OCULAR THERAPEUTIX, INC [ OCUL ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Legal Officer

3. Date of Earliest Transaction (Month/Day/Year)
10/08/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	10/08/2025		S(1)		11,132(1)	D	$12.34(2)	87,568	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Represents shares of common stock of Ocular Therapeutix, Inc. (the "Corporation") sold, pursuant to a durable automatic sale instruction adopted by the reporting person on October 7, 2024, effecting the sell-to-cover election of the reporting person to satisfy tax withholding obligations in connection with the vesting of restricted stock units on October 7, 2025. The sales do not represent a discretionary trade by the reporting person.

2. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $12.00 to $12.5114, inclusive. The reporting person undertakes to provide to the Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) to this Form 4.

Remarks:

Exhibit 24 - Power of Attorney

	/s/ Todd Anderman	10/10/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What did OCUL insider Todd Anderman sell on 10/08/2025?

The insider sold 11,132 shares of OCUL common stock under a sell-to-cover instruction on 10/08/2025.

Why were the OCUL shares sold by the reporting person?

The shares were sold to satisfy tax withholding obligations related to the vesting of restricted stock units and were executed under an automatic plan adopted on 10/07/2024.

What price did the OCUL shares sell for?

The disclosed weighted-average sale price was $12.34, with individual transaction prices ranging from $12.00 to $12.5114.

How many OCUL shares does the reporting person own after the sale?

After the reported transaction, the reporting person beneficially owns 87,568 shares.

Was the sale a discretionary trade by the reporting person?

No. The sale was executed under a durable automatic sale instruction and the reporting person stated it was not a discretionary trade.